Weil Advised Eli Lilly in its $1 Billion Acquisition of Prevail Therapeutics
Weil advised Eli Lilly and Company in its $1 billion acquisition of Prevail Therapeutics Inc., a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The transaction closed on January 12, 2021.
The Weil team that advised Eli Lilly was led by Mergers & Acquisitions partner Raymond Gietz and included Mergers & Acquisitions partner Matthew Gilroy and Mergers & Acquisitions associates Dov Kogen, Bilal Chaudhry and Tom Tsatsis. The team also included Technology & IP Transactions partner Jeffrey Osterman; Technology & IP Transactions/Privacy associate Kane Wishart; Executive Compensation & Benefits partner Amy Rubin; Executive Compensation & Benefits associate Tricia Walsh; and Tax partner Helyn Goldstein.
More from the Weil Tax Blog
Copyright © 2024 Weil, Gotshal & Manges LLP, All Rights Reserved. The contents of this website may contain attorney advertising under the laws of various states. Prior results do not guarantee a similar outcome. Weil, Gotshal & Manges LLP is headquartered in New York and has office locations in Boston, Brussels, Dallas, Frankfurt, Hong Kong, Houston, London, Miami, Munich, New York, Paris, Shanghai, Silicon Valley and Washington, D.C.